Cefixime Shortage: What Providers and Prescribers Need to Know in 2026

Cefixime Supply in 2026: A Provider Briefing

Cefixime (Suprax), a third-generation oral cephalosporin with a well-established role in outpatient infectious disease management, has become increasingly difficult for patients to locate at retail pharmacies. While not currently listed on the FDA or ASHP drug shortage databases, practical access barriers — limited manufacturers, inconsistent pharmacy stocking, and supply chain fragility — are causing patient-level dispensing delays.

This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and tools available to help your patients fill their prescriptions.

Timeline and Supply Background

Cefixime was FDA-approved in 1989 and has been available generically since its patent expiration. The drug's U.S. market history includes a notable disruption: brand-name Suprax was withdrawn from the market in 2002 by Wyeth and subsequently reintroduced in 2004 by Lupin Pharmaceuticals.

Currently, generic Cefixime is manufactured primarily by Lupin Pharmaceuticals and Aurobindo Pharma. This limited manufacturer base creates vulnerability — a production delay or quality hold at either facility can significantly impact national supply. The broader context of global antibiotic API sourcing adds additional risk, as most active ingredients are manufactured overseas.

As of Q1 2026, Cefixime is not on the FDA Drug Shortages list or the ASHP Current Shortages list. However, anecdotal and patient-reported data suggest inconsistent availability at the pharmacy level, particularly at large chain pharmacies.

Prescribing Implications

Cefixime's FDA-approved indications include:

• Uncomplicated urinary tract infections
• Otitis media
• Pharyngitis and tonsillitis
• Acute exacerbations of chronic bronchitis
• Uncomplicated gonorrhea (cervical/urethral)

Gonorrhea Treatment Considerations

Cefixime has historically been an important oral option for gonorrhea treatment. However, the CDC's current STI treatment guidelines recommend Ceftriaxone 500 mg IM as first-line therapy for uncomplicated gonorrhea, with Cefixime 800 mg oral as an alternative when Ceftriaxone is not available. Providers should be aware that if prescribing Cefixime for gonorrhea, ensuring the patient can actually fill the prescription is critical for public health outcomes.

Pediatric Prescribing

Cefixime remains a valuable option in pediatric populations (≥6 months) for otitis media and pharyngitis, particularly at 8 mg/kg/day dosing. The oral suspension (100 mg/5 mL, 200 mg/5 mL, 500 mg/5 mL) and chewable tablets (100 mg, 150 mg, 200 mg) provide dosing flexibility. However, verify pharmacy availability before prescribing, as liquid formulations may be less commonly stocked than capsules.

Drug Interactions to Note

Key interactions to document and monitor:

• Warfarin: Increased prothrombin time and bleeding risk — monitor INR closely
• Carbamazepine: Elevated carbamazepine levels reported in post-marketing surveillance
• Probenecid: Increases Cefixime blood levels by decreasing renal excretion

For complete interaction information, see Cefixime Drug Interactions: What to Avoid.

Current Availability Picture

The availability landscape for Cefixime in 2026 can be characterized as follows:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not routinely stock Cefixime, ordering on demand instead. This creates 1–2 day delays for patients.
• Independent pharmacies: Generally better availability due to multiple wholesaler relationships and more responsive ordering practices.
• Hospital outpatient pharmacies: May have better supply through hospital-specific distribution channels.
• Mail-order pharmacies: Online pharmacies (Amazon Pharmacy, Cost Plus Drugs, Honeybee Health) may carry generic Cefixime, though shipping timelines (2–5 days) make this less suitable for acute infections.

Providers can direct patients to Medfinder for Providers to check real-time pharmacy stock before patients leave the clinic.

Cost and Access Considerations

Cost can be a barrier or facilitator for access:

• Generic Cefixime cash price: $50–$85 for a standard course (e.g., 2 × 400 mg capsules)
• With discount card: $14–$20 (SingleCare, GoodRx, RxSaver)
• Brand-name Suprax: $150–$250+
• Insurance (Tier 2 generic): Typically $5–$20 copay

No manufacturer copay cards or savings programs are currently available for generic Cefixime or brand Suprax. Patient assistance through organizations like Prescription Hope ($70/month for Suprax) and NeedyMeds may help qualifying patients.

Recommending patients use discount cards at the point of prescribing can meaningfully improve fill rates. Consider noting "discount card acceptable" on prescriptions or discussing cost proactively with patients.

Tools and Resources for Your Practice

Real-Time Stock Checking

Medfinder for Providers allows your staff to verify pharmacy stock before sending a prescription, reducing callbacks and patient frustration. Integrating this check into your prescribing workflow can prevent the cycle of unfilled prescriptions and patient no-shows.

Alternative Antibiotics Reference

When Cefixime is unavailable, consider these evidence-based alternatives based on indication:

IndicationAlternativesUTI (uncomplicated)Cefpodoxime 100 mg BID × 7d; Nitrofurantoin 100 mg BID × 5d; TMP-SMX DS BID × 3dOtitis mediaCefdinir 300 mg BID × 10d; Cefpodoxime 200 mg BID × 10d; Amoxicillin-ClavulanatePharyngitis/tonsillitisCefdinir 300 mg BID × 10d; Cephalexin 500 mg BID × 10d; Penicillin V 500 mg BID × 10dGonorrheaCeftriaxone 500 mg IM (preferred); Gentamicin 240 mg IM + Azithromycin 2g PO (if cephalosporin-allergic)Acute bronchitis exacerbationCefdinir 300 mg BID; Cefpodoxime 200 mg BID; Azithromycin 500 mg day 1, 250 mg days 2–5

For a patient-facing version, see Alternatives to Cefixime.

Looking Ahead

The broader trend of antibiotic supply chain consolidation continues to pose risks for medications like Cefixime that have limited manufacturers and relatively low prescribing volume. Key developments to watch:

• FDA antibiotic incentive programs: The PASTEUR Act and similar legislation may improve economic viability for antibiotic manufacturers
• Antimicrobial stewardship implications: Supply disruptions can inadvertently drive prescribing toward less optimal antibiotics, potentially affecting resistance patterns
• Gonorrhea resistance surveillance: As Cefixime serves as a backup gonorrhea treatment, maintaining supply is a public health priority

Final Thoughts

Cefixime remains a clinically valuable oral cephalosporin, but its practical availability requires proactive management. The most effective approach for providers is to:

1. Verify pharmacy stock before prescribing (via Medfinder or direct pharmacy contact)
2. Have alternative regimens ready for each indication
3. Discuss cost and discount cards with patients proactively
4. Direct patients having difficulty to independent pharmacies or online options

For a complementary provider resource on helping patients navigate Cefixime access, see How to Help Your Patients Find Cefixime in Stock: A Provider's Guide. For cost-saving guidance to share with patients, see How to Help Patients Save Money on Cefixime.